The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions

Gennaro Chiappetta, Paolo Toti, Francesco Cetta, Ada Giuliano, Francesca Pentimalli, Ida Amendola, Stefano Lazzi, Mario Monaco, Luca Mazzuchelli, Piero Tosi, Massimo Santoro, Alfredo Fusco

Research output: Contribution to journalArticlepeer-review

Abstract

Hurthle cell adenomas and carcinomas, characterized by the presence of oncocytic cells, are unusual thyroid neoplasms, the treatment of which is still controversial. We analyzed specimens from 49 patients with oncocytic cell nodular lesions including 20 adenomas, 19 carcinomas, and 10 hyperplasias for RET/PTC (papillary thyroid carcinoma) activation, which is the most frequent genetic alteration in PTCs. RET/PTC activation was detected in a significant number of cases of Hurthle cell adenomas and carcinomas, but in 0 of 10 patients with hyperplastic nodules. In particular, the RET/PTC1 isoform was found in 7 of 12 adenomas and 4 of 7 carcinomas. These results would indicate that RET/PTC is a genetic event common to papillary carcinomas and to Hurthle cell neoplasias.

Original languageEnglish
Pages (from-to)364-369
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume87
Issue number1
DOIs
Publication statusPublished - 2002

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Fingerprint

Dive into the research topics of 'The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions'. Together they form a unique fingerprint.

Cite this